Amphastar Pharmaceuticals Inc (NAS:AMPH)
$ 46.09 -7.31 (-13.69%) Market Cap: 2.26 Bil Enterprise Value: 3.02 Bil PE Ratio: 14.73 PB Ratio: 3.10 GF Score: 88/100

Amphastar Pharmaceuticals Inc at Raymond James Human Health Innovation Conference (Virtual) Transcript

Jun 22, 2021 / 06:00PM GMT
Release Date Price: $20.2 (+0.10%)
Elliot Wilbur
Raymond James Financial - Analyst

Good afternoon. Welcome to the Amphastar Pharmaceuticals presentation at Raymond James annual Health and Human Innovation Conference. Pleased to welcome the Company here with us this afternoon. Representing the management, we have Dan Dischner, who heads the Company's Corporate Communication effort. We are also joined by Bill Peters, Amphastar's CFO; and Jacob Liawatidewi, who is the Company's Vice President of Sales and Marketing.

For those not familiar with the Amphastar story, Amphastar is a specialty generics company focused on injectable and inhalation products, with development capabilities targeting complex specialty generics, biosimilars, and 505(b)(2)-branded products. With that, I'm going to turn the forum over to Dan Dischner, who is going to provide us with an update, and then we will move into Q&A session. Dan?

Dan Dischner
Amphastar Pharmaceuticals, Inc. - VP of Corporate Communications

Yes. Good morning or afternoon, depending on where you are. Before I begin, I want to thank Raymond

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot